MCM
FPRX

Matarin Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Matarin Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-16,975
Closed -$614K – 309
2017
Q1 		$614K Sell
16,975
-111,686
-87% -$4.92M 0.06% 215
2016
Q4 		$6.45M Buy
128,661
+11,358
+10% +$597K 0.72% 38
2016
Q3 		$6.16M Buy
117,303
+80,898
+222% +$3.86M 0.68% 52
2016
Q2 		$1.51M Buy
+36,405
New +$1.58M 0.2% 152

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Matarin Capital Management's FPRX Position: Q2 2017 in Review

Matarin Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2017, closing a stake of 16,975 shares — an estimated $614K sold.

Matarin Capital Management first reported a position in FPRX in Q2 2016 and held it in 4 quarters. The position peaked at $6.45M in Q4 2016. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

  • Matarin Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Matarin Capital Management sold 16,975 Five Prime Therapeutics, Inc. shares in Q2 2017, an estimated $614K.
  • Matarin Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 4 quarters.
  • Matarin Capital Management's Five Prime Therapeutics, Inc. position peaked at $6.45M in Q4 2016.
  • 123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on Matarin Capital Management's 13F filing for Q2 2017, filed 9 Aug 2017.